



Process and status of vaccine recommendations

National Adult and Influenza Immunization
Summit



The number of immunocompromised patients is increasing; by some accounts, it may be as high as 6% of the US population.

These patients are at higher risk from infections and receive less protection from vaccines.

JAMA

Published Online: February 15, 2024

2024;331;(10):880-
882. doi:10.1001/jama.2023.28019

All immunocompromised patients are not the same



People with HIV
infection

Solid organ
transplant recipients

Hematopoietic cell
transplant (HCT)
and CAR-T therapy
recipients



Individuals with
hematologic
malignancies

Patients receiving
chemotherapy for
solid tumors



Individuals with
primary
immunodeficiency
disorders or
autoimmune or
inflammatory
conditions
receiving
immunosuppressive
or biologic
therapies

Vaccine recommendations for immunocompromised patients



1

COVID-19 guidelines for immunocompromised patients will be available next week, followed shortly by flu and RSV.

2

A diverse panel of clinical experts following an Evidence-to-Recommendations framework.

3

The recommendations are informed by the systematic data review from VIP.

Respiratory virus vaccines


<https://www.idsociety.org/>

Expect guidelines by the end of October


One recommendation for each vaccine

- **Specific implementation guidance for the various groups within the immunocompromised populations.**

Guidelines will be published in
Clinical Infectious Diseases



<https://academic.oup.com/cid>



Contact info:

Eli Briggs
Director of Public Policy
ebriggs@idsociety.org